Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six abstracts have been accepted for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting, to be held December 12-16, 2026, in New Orleans, LA. The presentations include new analyses providing further insight into the clinical activity and approved dosing regimen of RYTLEO® (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS).

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.